Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 279 No 7470 p325
22 September 2007

This article
Reprint   Photocopy

PDF 40K, Acrobat Reader

Letters

• Sponsored inserts (3)
• Dose administration aids
• White Paper
• Prescribing
• 100-hour pharmacies
• Retention fees
• The Society (2)


Letters to the Editor

Dose administration aids

Australian government sees sense (will ours take notice?)

From Mr P. Williams, MRPharmS

I was interested to read that the Government of Australia is funding a programme for retail pharmacists to supply packaged medicines — or dose administration aids (DAAs) as they refer to them — for older patients and those on multiple medicines to the value of A$72.9m, as part of a fourth pharmacy agreement.

The programme, which will be managed by the Pharmacy Guild of Australia with the support of the Pharmaceutical Society, follows the identification of “significant heath benefits of the service” in the research and development programme of the third community pharmacy agreement.

This is heartening to read. However, it does make me even more frustrated about the lack of recognition the benefits of such aids receives by our own Government. I hope the powers that be follow this programme closely and it encourages them to provide the same support for pharmacies in the UK.

I have been championing the use of such aids for years and I know pharmacists — including myself — witness real benefits to patients’ health and are using them more and more. For example, sales of our PlusPak products are increasing by 50 per cent year on year, yet through the new contract we receive little funding to support this, meaning many pharmacists are providing these services out of goodwill.

It seems the message has got through in Australia with the guild describing DAAs as “commonly used medication management devices that lead to improved quality of life and better health outcomes for patients through improved quality use of medicines. Along with regular pharmacy interaction, DAAs can reduce adverse drug events and improve the patient’s ability to manage their medicines”.

I could not have put it better myself. I just hope to see the same supportive and proactive approach by our Government in the not too distant future but I am not holding my breath.

P. Williams
Pharmacy Proprietor and Managing Director,
MTS Medication Technologies,
Darwen, Lancashire

Send your letter to The Editor

Previous Topic (Sponsored inserts)
Next Topic (White Paper)

Back to Top


©The Pharmaceutical Journal